摘要:
Method for impregnating lignocellulosic material with effect agents, comprises impregnating the lignocellulosic material with a fluid formation, which contains at least one effect agent in a dissolved or dispersed form; impregnating the material with a hardenable aqueous composition, which contains at least one cross-linkable compound; and treating the material obtained at an elevated temperature. Method for impregnating lignocellulosic material with effect agents, comprises impregnating the lignocellulosic material with a fluid formation, which contains at least one effect agent in a dissolved or dispersed form; impregnating the material with a hardenable aqueous composition, which contains at least one cross-linkable compound such as low-molecular weight compounds (V), having at least two N-bonded groups of formula (CH2OR) and/or one 1,2-bishydroxyethane-1,2-diyl group, bridging two nitrogen atoms, precondensates the compound (V), and reaction products or mixtures of the compound (V) with at least one alcohol such as 1-6C alkanols, 2-6C polyols and oligoalkylene glycols; and treating the material obtained at an elevated temperature. R : H or 1-4C alkyl. Independent claims are also included for: (1) a lignocellulosematerial, is obtained by the process; and (2) an aqueous composition comprising dissolved or dispersed form of effect agent and hardenable compound.
摘要:
A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-KB as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 µm/mL.
摘要:
Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar and Ar are optionally substituted heteroaryl or optionally substituted phenyl; X is -O-, -S-, -SO-, -SO2-, -NR -, -NCOR - or -NR SO2R ; (a) is selected from the group consisting of (b), (c), (d) and (e); X is -O-, -S- or -NR -; Y is =O, =S or =NR ; Y is H, C1-C6 alkyl, -NR R , -SCH3, R -aryl(CH2)n6-, R -heteroaryl-(CH2)n6-, -(CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R ; R is H or -(CH2)n1-G, wherein n1 is 0-5 G is H, -CF3, -CHF2, -CH2F, -OH, -O-(C1-C6 alkyl), -SO2R , -O-(C3-C8 cycloalkyl), -NR R , -SO2NR R , -NR SO2R , -NR COR , -NR (CONR R ), -CONR R , -COOR , C3-C8 cycloalkyl, R -aryl, R -heteroaryl, and provided when n1=0, G is not H; R , R , R and R are H, alkyl, cycloalkyl, -CHF2, -CH2F or -CF3; or R and R , together with the carbon to which they are attached, form an alkylene ring; or R and R together are =O; R is R or -OH; and the remaining variables are as defined in the specifiation, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds, and pharmaceutical compositions comprising said compounds are disclosed. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor.
摘要翻译:由结构式(I)表示的化合物或其药学上可接受的盐,其中Ar 1和Ar 2是任选取代的杂芳基或任选取代的苯基; X 1是-O - , - S - , - SO - , - SO 2 - , - NR 12 - , - NR C 12 - 或-NR 12 SO 2 R 15。 (a)选自(b),(c),(d)和(e); X 2是-O - , - S-或-NR 5 - ; Y = O,= S或= NR 11; Y 1是H,C 1 -C 6烷基,-NR 17 R 13,-SCH 3,R 19 - 芳基(CH 2)n6-,R 19 - 杂芳基 - (CH 2)n6-, - (CH 2)n 6-杂环烷基, - (C 1 -C 3)烷基-NH-C(O)O(C 1 -C 6)烷基或-NHC(O)R 15; R 5是H或 - (CH 2)n1-G,其中n1是0-5G是H,-CF3,-CHF2,-CH2F,-OH,-O-(C1-C6烷基),-SO2R 13 C,-O-(C 3 -C 8环烷基),-NR 13 R 14,-SO 2 NR 13 R 14,-NR 13 SO 2 R 15,-NR 13 COR R 12,-NR 12(CONR 13 R 14),-CONR 13 R 14,-COOR 12,C 3 -C 8环烷基,R 19 - 芳基,R 19 当n1 = 0时,G不为H; R 1,R 2,R 3和R 7是H,烷基,环烷基,-CHF 2,-CH 2 F或-CF 3; 或R 1和R 2与它们所连接的碳一起形成亚烷基环; 或R 1和R 2一起为= O; R 6是R 7或-OH; 并且剩余的变量如规定中所定义,治疗易受神经激肽拮抗剂治疗的疾病的方法,以及包含所述化合物的药物组合物。 还公开了包含有效量的权利要求1的化合物,至少一种药学上可接受的载体和与有效量的选择性5-羟色胺再摄取抑制剂组合的药物组合物。
摘要:
Novel polyfunctional glyoxylated compounds represented by formula (I) wherein n is a whole positive integer of at least 2; wherein Y is (a), (b) or (c); wherein A is -NH- or -O-; wherein R is the residue of a poly(active hydrogen group)-containing compound after abstraction of n active hydrogen-containing groups, wherein the active hydrogen groups are selected from hydroxyl and amino grops; wherein R is hydrogen, an alkyl group having from 1 to 4 carbon atoms, a hydroxymethyl or an alkoxymethyl group having 2 to 4 carbon atoms; and wherein each R is H or an alkyl group having from 1 to 6 carbon atoms; and compositions containing the same are disclosed which are particularly suitable for use as crosslinking components in curable compositions and also find use in imparting wet adhesion properties to water-based paints and coatings. A process for preparing novel polyfunctional glyoxylated compounds is also disclosed.
摘要:
Provided herein are lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitors, pharmaceutical compositions of said inhibitors, and methods of their use for the treatment of disease.
摘要:
The present invention provides novel bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the bicyclic carbocyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in modulation of normal function of the target RNA. In certain embodiments, bicyclic carbocyclic nucleosides are provided as monomers for use as antivirals.
摘要:
The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a patient in need of therapy for an androgen receptor associated condition by administering a therapeutically effective amount of at least compound of the present invention.
摘要:
The present invention relates to novel sulfoxide and bis-sulfoxide compounds, compositions comprising sulfoxide and bis-sulfoxide compounds, and methods useful for treating and preventing caridovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
摘要:
Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ar and Ar are optionally substituted heteroaryl or optionally substituted phenyl; X is -O-, -S-, -SO-, -SO2-, -NR -, -NCOR - or -NR SO2R ; (a) is selected from the group consisting of (b), (c), (d) and (e); X is -O-, -S- or -NR -; Y is =O, =S or =NR ; Y is H, C1-C6 alkyl, -NR R , -SCH3, R -aryl(CH2)n6-, R -heteroaryl-(CH2)n6-, -(CH2)n6-heterocycloalkyl, -(C1-C3)alkyl-NH-C(O)O(C1-C6)alkyl or -NHC(O)R ; R , R , R and R are H, alkyl, cycloalkyl, -CHF2, -CH2F or -CF3; or R and R , together with the carbon to which they are attached, form an alkylene ring; or R and R together are =O; R is R or -OH; and the remaining variables are as defined in the specification, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds. Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor.
摘要翻译:由结构式(I)表示的化合物或其药学上可接受的盐,其中Ar 1和Ar 2是任选取代的杂芳基或任选取代的苯基; X 1是-O - , - S - , - SO - , - SO 2 - , - NR 12 - , - NR C 12 - 或-NR 12 SO 2 R 15。 (a)选自(b),(c),(d)和(e); X 2是-O - , - S-或-NR 5 - ; Y = O,= S或= NR 11; Y 1是H,C 1 -C 6烷基,-NR 17 R 13,-SCH 3,R 19 - 芳基(CH 2)n6-,R 19 - 杂芳基 - (CH 2)n6-, - (CH 2)n 6-杂环烷基, - (C 1 -C 3)烷基-NH-C(O)O(C 1 -C 6)烷基或-NHC(O)R 15; R 1,R 2,R 3和R 7是H,烷基,环烷基,-CHF 2,-CH 2 F或-CF 3; 或R 1和R 2与它们所连接的碳一起形成亚烷基环; 或R 1和R 2一起为= O; R 6是R 7或-OH; 并且其余变量如本说明书中所定义,治疗易受神经激肽拮抗剂治疗的疾病的方法。 还公开了包含有效量的权利要求1的化合物,至少一种药学上可接受的载体和与有效量的选择性5-羟色胺再摄取抑制剂组合的药物组合物。